Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) published a letter to shareholders from CEO Kelvin Cooper, Ph.D., on September 21, 2026, reviewing a quarter in which it listed on the Nasdaq Capital Market, completed a $7.5 million private placement and prepared Nu-3 for the upcoming Phase 2a trial in infected diabetic foot ulcers.

Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: [https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1](https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1)

The Phase 2a program rests on preclinical data, clinical leadership and a larger patent estate:

• Preclinical safety findings showed low systemic exposure after topical administration and no interference with wound healing, supporting 2%, 5% and 10% dose strengths for the trial

• In comparative preclinical studies, Nu-3 showed rapid, broad-spectrum activity against multidrug-resistant pathogens without generating resistance

• David G. Armstrong, DPM, MD, Ph.D., is Study Chair and Scientific Advisor; the study is led by Professional Education and Research Institute (PERI) under Charles M. Zelen, DPM

• A new Australian composition-of-matter patent brings the portfolio to 72 granted patents and 29 pending applications

In the letter, Kelvin Cooper wrote: "Our priorities are clear: initiate and advance Nu-3 through Phase 2 clinical development, generate the clinical evidence necessary to demonstrate its potential in infected diabetic foot ulcers, and continue building the foundation for the broader development of our Bisphosphocin® platform."

Read the full release: [https://lakewoodamedex.investorroom.com/2026-09-21-Lakewood-Amedex-Biotherapeutics-CEO-Issues-Letter-to-Shareholders-Highlighting-Transformational-Progress-and-Outlook-for-Nu-3](https://lakewoodamedex.investorroom.com/2026-09-21-Lakewood-Amedex-Biotherapeutics-CEO-Issues-Letter-to-Shareholders-Highlighting-Transformational-Progress-and-Outlook-for-Nu-3)

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit [https://lakewoodamedex.com](https://lakewoodamedex.com/).

Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com.

B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at [https://b2idigital.com/disclaimer](https://b2idigital.com/disclaimer).

Lakewood-Amedex Biotherapeutics (Nasdaq: LABT) CEO Kelvin Cooper issues a letter to shareholders on Nu-3's path to Phase 2a, a $7.5 million placement and 72 granted patents.